KPV is a research compound. It is not approved by the FDA or any regulatory body for human use. This article is for educational and informational purposes only. Nothing here constitutes medical advice. Consult a qualified physician before considering any peptide use.
KPV is being researched for inflammation applications. Inhibits nuclear factor-kappa B (NF-κB) activation through PepT1 transporter-mediated cellular uptake, completely independent of melanocortin receptors. Blocks NF-κB nuclear import and suppresses pro-. Common dosages for this use range from 200-500 mcg daily once or twice daily.
Can KPV Help With Inflammation?
KPV (Lysine-Proline-Valine tripeptide) is being researched for inflammation applications based on its mechanism as a Alpha-MSH fragment, NF-κB inhibitor.
Inhibits nuclear factor-kappa B (NF-κB) activation through PepT1 transporter-mediated cellular uptake, completely independent of melanocortin receptors. Blocks NF-κB nuclear import and suppresses pro-inflammatory cytokines (TNF-α, IL-6, IL-1β) at nanomolar concentrations. Also inhibits MAPK inflammatory signaling cascade.
What Does the Research Show for KPV and Inflammation?
Demonstrated significant colitis reduction in DSS and TNBS-induced models with decreased inflammatory cytokine expression. Multiple peer-reviewed studies confirm NF-κB inhibition at nanomolar concentrations. Zero human clinical trials completed; preclinical evidence strong for inflammatory bowel disorders.
The relevance to inflammation specifically comes from KPV's effects on anti-inflammatory, IBD reduction, intestinal barrier repair, skin inflammation reduction, immune modulation.
What Protocol Is Used for Inflammation?
For inflammation applications, the standard KPV protocol is 200-500 mcg daily administered once or twice daily via oral (most studied), intranasal, subcutaneous for 4-8 weeks.
Some researchers adjust dosing based on the specific inflammation application — see our KPV dosage guide for full protocol details.
Can Stacking Improve Inflammation Results?
Pairs synergistically with BPC-157 for comprehensive gut healing — KPV handles inflammation through NF-κB while BPC-157 promotes tissue repair through growth factor pathways.
What Side Effects Apply to Inflammation Use?
No serious adverse events in preclinical studies. Theoretical potential for immune suppression at very high doses given NF-κB inhibition. GI upset possible with oral administration.
Side effects are generally consistent regardless of the specific application. See our KPV side effects guide for details.
Calculate Your KPV Dose
Use our free peptide dosing calculator to get exact reconstitution math and syringe units for KPV.
Open Calculator →Bottom Line: KPV for Inflammation
KPV shows preliminary research potential for inflammation. Standard protocols (200-500 mcg daily, once or twice daily, 4-8 weeks) apply.
Source from COA-tested vendors and maintain consistent dosing for the full cycle duration.
Complete Guide
KPV : Benefits, Dosage, Side Effects & Research
Related Reading
Research-Grade Sourcing
If you're going to research KPV, source matters. These are the suppliers WolveStack has vetted for purity and third-party testing.
Frequently Asked Questions
What is KPV?
KPV (Lysine-Proline-Valine tripeptide) is a Alpha-MSH fragment, NF-κB inhibitor. C-terminal tripeptide fragment of alpha-melanocyte-stimulating hormone (α-MSH), naturally occurring from proteolytic cleavage. It is researched for anti-inflammatory, IBD reduction, intestinal barrier repair, skin inflammation reduction, immune modulation.
What is the recommended KPV dosage?
Common dosages: 200-500 mcg daily administered once or twice daily via oral (most studied), intranasal, subcutaneous. Cycle length: 4-8 weeks. Half-life: not published. Use our peptide calculator for exact reconstitution math.
What are the side effects of KPV?
No serious adverse events in preclinical studies. Theoretical potential for immune suppression at very high doses given NF-κB inhibition. GI upset possible with oral administration.
Is KPV safe?
KPV has shown a preliminary safety profile in research. Not FDA-approved. Expected to move from FDA Category 2 to Category 1 (allowing licensed compounding) based on 2026 regulatory developments. All research should follow appropriate safety protocols.